Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2004

View Archived Issues

Bevacizumab reported to increase antitumor effects of FOLFOX4 chemotherapy in colorectal cancer

Citrus bioflavonoid naringin and lovastatin show comparable hypocholesterolemic effects in vivo

Phase I data suggest a favorable safety profile for APD-356 in obese subjects

HuMax-EGFr shows promise in the treatment of head and neck cancer

Garlic derivative may attenuate intestinal inflammation

EP-2306 and EP-2302 effectively inhibit LDL oxidation, possible application in atherosclerosis

p38 kinase inhibitors claimed in three GlaxoSmithKline patents

Fournier prepares and tests new bradykinin B1 antagonists for treatment of pain

Pfizer presents novel antibacterial oxazolidinones

Researchers at Dynogen describe a new treatment for urinary tract disorders

Putative metabolites of rosiglitazone described in a patent

Scientists at Merck describe novel series of serotonin antagonists

New RXR antagonists in early development at Novartis for diabetes and diabetic complications

KXS-01: novel antiangiogenic agent prevents endothelial cell proliferation and migration in vitro

LXT-101, a novel GnRH antagonist, potently reduces testosterone levels in male rats

Icatibant induces pain relief in patients with osteoarthritis of the knee

Lumiracoxib reported as effective as celecoxib in OA of the knee

Imatinib shows activity in AIDS-related Kaposi's sarcoma

Certican approval extended to new E.U. member states

ODAC votes against recommending approval of Marqibo

NovaCal IND cleared for phase II trials of NVC-101

Fast track designation for CG-53135 for prevention of oral mucositis

New data on mechanism of action of PCK-3145

Allon Therapeutics reviews Q3 highlights

Medical Discoveries files IND for phase I cystic fibrosis study of MDI-P

Kyorin to acquire ActivX Biosciences

Launch of Fuzeon Accelerated Simultaneous Access Program

Guilford to acquire ProQuest

Low-dose PW-2101 fails to meet primary endpoint in pivotal hypertension study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...